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Introduction
Diabetes is caused by deficiency or malfunction of pancreatic β 
cells. Our understanding of the mechanisms underlying β cell 
maintenance and failure in humans has been hampered by the 
scarcity of material available for research. It is hence a major 
breakthrough that 2 functional human β cell lines, termed EndoC-
βH1 and EndoC-βH2, have recently become available (1, 2).
EndoC-βH1/2 cell lines were developed from human fetal 
pancreatic buds. Pancreatic cells were transduced with lentivec-
tors encoding SV40 T antigen and human telomerase and ampli-
fied through several passages as xenotransplants in SCID mice (1, 
2). Cell lines developed by this method are at risk of infection by 
endogenous xenotropic murine leukemia viruses (X-MuLVs) (3). 
X-MuLVs are gammaretroviruses that infect proliferating cells 
from most mammalian species, including human and wild mice, 
through a receptor encoded by the Xpr1 gene (4, 5). Most mouse 
laboratory strains are refractory to infection by X-MuLVs because 
they express a restrictive allele of Xpr1 (Xpr1n). They still harbor 
X-MuLVs as endogenous retroviruses, probably because the germ 
cells of their wild ancestors were infected before the acquisition 
of Xpr1n (5). X-MuLVs were first isolated from NZB mice and then 
were found in most laboratory mouse strains (5). Production of 
infectious X-MuLV particles depends on the strain carrying the 
provirus. They are produced throughout life by NZB and F/St 
mice. In most other strains, viruses are barely (or not at all) detect-
able, although their production can be induced by immune stimuli 
such as xenotransplantation (5).
Contamination of xenografted human cells by endogenous 
X-MuLVs has been reported since the 1970s, but few studies have 
provided comprehensive data regarding origin, expression, titer, 
propagation, and transcomplementation properties of the invad-
ing virus. We report here that human EndoC-βH1/2 cells contain 
several copies of B10 xenotropic virus 1 (Bxv1), probably acquired 
during their expansion in SCID mice. Exposure of human cells 
to EndoC-βH1/2 cell–conditioned medium turns them into Bxv1 
infected and producing cells. However, this propagation is poorly 
efficient, possibly because Bxv1 titers in EndoC-βH1/2–condi-
tioned medium are relatively low. Finally, we show that Bxv1 trans-
complements MuLV-based retrovectors.
Results and Discussion
EndoC-βH1 cells express a xenotropic envelope protein. To generate 
new mAbs against human pancreatic β cell surface markers, we 
created a hybridoma library from mice immunized with cultured 
EndoC-βH1 cells (Kirkegaard et al., unpublished observations). 
One of these mAbs, termed 13F25, stained plasma membranes of 
EndoC-βH1, but not HepG2, cells, which are a human hepatoma–
derived cell line (Figure 1A). The detected protein was concentrat-
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To test whether Bxv1 is present in SCID mice used for xeno-
transplantation and determine whether EndoC-βH1/2 cells contain 
a complete proviral genome, we selected PCR primers to amplify 
the Bxv1 genome. The 8 overlapping PCR fragments covered 7,605 
bp out of the 8,662 bp of the Bxv1 genome, excluding long termi-
nal repeat (LTR) sequences (Figure 2B). When tested on genomic 
DNA, these primers amplified products of identical size in EndoC-
βH1 and SCID mice, whereas no amplification occurred in 293T 
cells (Figure 2C). All PCR products were sequenced and revealed 
100% sequence identity between SCID mice and EndoC-βH1 cells 
and only 1 single nucleotide mismatch with the published Bxv1 
sequence. These data strongly suggested that EndoC-βH1 cells 
contained at least 1 complete Bxv1 genome and became infected 
during their passaging in SCID mice. Using quantitative PCR, 
EndoC-βH1 and EndoC-βH2 were shown to contain 22–32 and 6–7 
(complete or partial) Bxv1 genomes, respectively. Finally, we tested 
the 13F25 mAb antibody on lysates from EndoC-βH1, HepG2, and 
VCaP, a human prostate cancer cell line producing infectious Bxv1 
particles (7). 13F25 bound to several bands around 65 kDa in both 
EndoC-βH1 and VCaP lysates, but not in HepG2 (Figure 2D), con-
firming that 13F25 indeed detects Bxv1 expression.
EndoC-βH1 cells produce replication-competent Bxv1 viruses. The 
presence of at least 1 complete Bxv1 genome in EndoC-βH1 cells 
and detection of Env in their medium (Figure 1B) led us to exam-
ine whether they produce viral particles. Proliferating 293T cells 
were exposed to EndoC-βH1 conditioned medium in the presence 
of polybrene. After 13 days (and 2 passages), reverse-transcriptase 
PCR (RT-PCR) using Bxv1 env primers indicated that 293T cells 
expressed viral mRNAs (Figure 3, A and B). Thus, EndoC-βH1 
cells produce replication-competent Bxv1 particles.
Bxv1 is a gammaretrovirus, a group of retroviruses whose 
defective derivatives are widely used as retrovectors (hereafter 
referred to as MuLV-based retrovectors). Both XMRV and the 
X-MuLV NZB transcomplement MuLV-based retrovectors (8, 
9). To test transcomplemention by Bxv1, we used as tester cells 
a 293T derivative, termed 293T-TVA-Hy, transduced with the 
ed at the plasma membrane, present in EndoC-βH1–conditioned 
medium, and glycosylated (Figure 1, A and B).
To identify the antigen recognized by 13F25, target proteins 
were purified by IP from both EndoC-βH1 lysates and conditioned 
medium. Isolated proteins were treated with PNGase F, separated 
by SDS-PAGE, and visualized by Coomassie staining. A protein 
of molecular weight around 65 kDa (Figure 1B), reduced to 50 
kDa after PNGase F treatment and absent in the isotype control, 
was excised from the gel and subjected to in-gel digestion with 
trypsin prior to liquid chromatography–mass spectrometry/mass 
spectrometry (LC-MS/MS) analysis. The identified peptides were 
mapped to a group of envelope proteins from X-MuLVs (Supple-
mental Figure 1; supplemental material available online with 
this article; doi:10.1172/JCI83573DS1). Thus, EndoC-βH1 cells 
express a X-MuLV envelope protein present at their plasma mem-
brane and in the culture medium, which suggests that they harbor 
and possibly produce a xenotropic retrovirus. This prompted us to 
determine the identity of the retrovirus and whether it is produced 
by EndoC-βH1 cells.
Bxv1 provirus in the genome of EndoC-βH1/2 cells and SCID 
mice. The close similarity between the envelope proteins from 
X-MuLVs precluded their distinction based on a partial protein 
sequencing. To identify the virus encoding the 65-kDa protein, 
proviral X-MuLV sequences were searched by genomic PCR. We 
used primers that amplify a large proportion of the sequence cod-
ing the envelope protein from numerous X-MuLVs on DNA from 
HeLa, 293T, 22Rv1, EndoC-βH1, and EndoC-βH2 cells. 22Rv1 
cells, our positive control, derive from a xenografted human 
prostatic cancer and produce high titers of xenotropic MuLV-
related virus) (XMRV), a retrovirus closely related to X-MuLVs 
(6). The primers amplified a 1,453-bp product in 22Rv1, EndoC-
βH1, and EndoC-βH2, but not in 293T or HeLa, cells (Figure 2A). 
Amplicon sequencing from EndoC-βH1 showed 100% iden-
tity with a sequence present on chromosome 1 of the C57BL/6J 
mouse genome. This location maps to an endogenous X-MuLV, 
Bxv1 (or Xmv43) (5).
Figure 1. 13F25 identifies expression of a xeno-
tropic envelope viral protein in EndoC-βH1 cells. 
(A) 13F25 mAb specifically binds to live EndoC-
βH1 and not HepG2. Insets show DAPI staining. 
n = 10. Scale bars: 50 μM. (B) Coomassie gels 
showing the proteins purified by IP from EndoC-
βH1 or conditioned medium using mAb 13F25 or 
the isotype control Ab. The proteins, indicated 
with arrowhead at approximately 65 kDa or arrow 
(after PNGase F treatment) at approximately 
50 kDa, were excised for identification by MS 
(n = 5 and 2 for IP from cells and from medium, 
respectively). See complete unedited blots in the 
supplemental material.
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derivative of EndoC-βH2 transduced with pPRiHy-TVA (EndoC-
βH2–TVA-Hy cells). 293T cells were exposed to the conditioned 
medium of EndoC-βH2–TVA-Hy cells. Selection of the resulting 
cells (293T-1, Figure 3A) showed that many of them had acquired 
hygromycin resistance (data not shown). Thus, the presence of 
Bxv1 in EndoC-βH2 cells led to MuLV-based retrovector mobiliza-
tion. Moreover, conditioned medium of 293T-1 cells transmitted 
hygromycin resistance to another batch of naive 293T cells, lead-
ing to 293T-2 cells whose conditioned medium again transmitted 
hygromycin resistance (leading to 293T-3 cells) (Figure 3, A and C). 
Bxv1 genome and transcripts were readily detected in 293T-1, -2, 
and -3 cells (Figure 3B and Supplemental Figure 2). Thus, each step 
reconstituted the replicative helper virus (Bxv1)/defective retro-
vector (pPRIHy-TVA) tandem, meaning that EndoC-βH2 (or 293T) 
cells coinfected by Bxv1 and a MuLV-based retrovector invariably 
released both types of viral particles. As expected, transient trans-
fection of MuLV-based retrovectors in EndoC-βH1 cells also led to 
their transcomplementation, which was abrogated upon deletion 
of their packaging sequence (data not shown).
Amphotropic, polytropic, and xenotropic retroviruses can 
infect human cells while mouse NIH3T3 fibroblasts are suscep-
tible to amphotropic and polytropic, but resistant to xenotro-
pic, viruses (4, 5, 9). NIHT3T3 cells exposed to the conditioned 
medium of EndoC-βH2–TVA-Hy cells did not display any resis-
tance to hygromycin, indicating that the retrovectors released 
by EndoC-βH2–TVA-Hy cells were not amphotropic or polytrop-
ic. Under the same conditions, NIH3T3 cells stably expressing 
human XPR1 (NIHT3T3-huXPR1) gave numerous hygromycin-
resistant foci (Figure 3, A and C). Thus, transduced EndoC-βH2 
pPRIHy-TVA MuLV–based retrovector (10). pPRIHy-TVA encodes 
no retroviral protein, but encodes hygromycin resistance (as well 
as the avian TVA receptor). Hygromycin resistance was used as 
a recordable marker for retrovector mobilization. 293T-TVA-Hy 
cells were exposed to EndoC-βH1–conditioned medium, lead-
ing to 293T-TVA-Hy*. Four weeks later, the conditioned medium 
from 293T-TVA-Hy* cells was in turn added to naive 293T cells 
(Figure 3A). Upon hygromycin selection, numerous resistant cells 
(293T*) were detected, demonstrating pPRIHy-TVA mobiliza-
tion in 293T-TVA-Hy* cells (Figure 3C). Importantly, 293T* cells 
(and, as expected, 293T-TVA-Hy* cells) were positive for the Bxv1 
genome and transcripts (Figure 3B and Supplemental Figure 2), 
indicating that secondary infected cells (293T-TVA-Hy*) not only 
produce all Bxv1 proteins required for pPRIHy-TVA mobilization, 
but also infectious Bxv1 particles. Naive 293T-TVA-Hy cells were 
negative for Bxv1 genome and transcripts (Figure 3B and Supple-
mental Figure 2), and their conditioned medium did not transmit 
hygromycin resistance (Figure 3C). In summary, Bxv1 transcom-
plements MuLV-based retrovectors and can be propagated from 
EndoC-βH1 to 293T cells, which hence turn into Bxv1 produc-
ers. However, Bxv1 expression is considerably lower in secondary 
infected cells compared with EndoC-βH1 cells (Figure 3B). Inter-
estingly, Bxv1 expression decreased 4-fold when EndoC-βH2 cells 
were withdrawn from the cell cycle upon stable expression of CRE 
recombinase (Figure 3B and ref. 2).
Bxv1 transcomplements defective MuLV-derived retrovectors in 
EndoC-βH1/2 cells. Results described above raised concerns regard-
ing the use of MuLV-based retrovectors in EndoC-βH1/2 cells. 
We carefully examined this potential pitfall using an unpublished 
Figure 2. Bxv1 genome is 
integrated in EndoC-βH1/2 
cells and SCID mice. (A) The 
sequence encoding the envelope 
protein from a broad range of 
xenotropic MuLV was amplified 
from genomic DNA from the 
indicated cell lines to generate 
the envelope protein-encoding 
fragment (P-ENV) PCR product 
(see B). HeLa and 293T cells are 
negative controls. (B) Position 
of the 8 PCR products covering 
the Bxv1 sequence. P0, primer 
set 0. (C) Amplification of Bxv1 
genome using the 8 overlap-
ping PCR fragments showing 
amplification in EndoC-βH1 cells 
and in SCID mice. Results are 
representative of 3 indepen-
dent experiments. (D) Western 
blot showing that VCaP and 
EndoC-βH1 lysates are positive 
for 13F25 (n = 6). See complete 
unedited blots in the supple-
mental material.
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infectivity test (11). The 22Rv1 cell line was included as a refer-
ence. Quantification was done after 7 days of culture using the 
50% tissue culture infective dose (TCID50) titration method 
(Table 1). We expressed virus titer as number of Bxv1 particles 
per number of EndoC-βH1/2 cells. EndoC-βH1 and EndoC-βH2 
cells produce 5.6 and 14 Bxv1 particles per 100 cells, respective-
ly, in agreement with the 4-fold higher expression of Bxv1 tran-
scripts in EndoC-βH2 compared with EndoC-βH1 (Figure 3B). 
This is more than 10-fold lower than the titer of XMRV in the 
conditioned medium of 22Rv1 cells (Table 1). These results con-
firmed that EndoC-βH1 and EndoC-βH2 produce replication-
competent virus, although at relatively low titers.
cells released retrovectors pseudotyped with the xenotropic 
envelope, confirming that they arose as a result of transcomple-
mentation by Bxv1.
Finally, we examined whether Bxv1 (or Bxv1 relatives) are also 
found in common rodent β cell lines. Both genomic sequences and 
transcripts from Bxv1, or closely related retroviruses, were detected 
in MIN6 and βTC3 cells (Supplemental Figure 3), consistent with the 
wide prevalence of endogenous xenotropic or polytropic retrovirus-
es among mouse laboratory strains (5). In contrast, rat INS-1E and 
RIN-5F cells were negative, despite the latter having been passaged 
in immunocompromised mice, suggesting that rat cells are not easily 
infected by endogenous X-MuLVs or fail to induce their production in 
mice. Importantly, all rodent cell lines were negative in Western blot 
experiments using the 13F25 antibody and only βTC3 cells showed 
a detectable transcomplementation activity, albeit at an extremely 
low level compared with EndoC-βH2 cells (Supplemental Figure 3). 
Thus, even though X-MuLVs are detected in 2 mouse β cell lines, only 
EndoC-βH1/2 cells show a marked ability to mobilize MuLV-based 
retrovectors under our culture conditions.
Quantification of virus production by EndoC-βH1/2 cells. Pro-
duction of replication-competent particles was next quantified 
in EndoC-βH1/2 cells using the classical PG4(S+L–) retrovirus 
Figure 3. Bxv1 infectious particles are produced by EndoC-βH1/2 cells and transcomplement MuLV-based retrovectors. (A) Procedure followed to study Bxv1 
propagation and transcomplementation properties. CM, conditioned medium. (B) Bxv1 expression was analyzed by real time RT-PCR with primers for its env 
gene. Relative mRNA level for each population is given. (C) Left: control 293T cells exposed to the conditioned medium of 293T-TVA-Hy cells (upper panel) or 
293T* (bottom panel) after selection in hygromycin, fixation, and coloration with crystal violet. Center: control 293T (upper panel) or 293T-3 cells (bottom panel). 
Right: parental NIH3T3 (upper panel) or NIH3T3-huXPR1 cells (bottom panel) exposed to the CM of EndoC-βH2–TVA-Hy cells. Propagation and transcomplemen-
tation properties of Bxv1 were evidenced in 6 and 5 independent experiments, respectively. Scale bar: 1 cm. An identical area is shown for each dish.
Table 1. Virus quantification
Cell line Titer TCID50/ml Particles produced/cell
EndoC-βH1 9.96 × 104 5.59 × 10–2
EndoC-βH2 1.31 × 105 1.38 × 10–1
22Rv1 2.42 × 107 2.23
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Overall, our data do not support concerns previously raised 
regarding the horizontal propagation of X-MuLVs (3, 12). Indeed, 
though the propagation of Bxv1 from EndoC-βH1/2 cells to other 
human cells is feasible, it appears markedly inefficient: (a) Bxv1 
mRNA expression is much lower in secondary infected 293T cells 
than in EndoC-βH1/2 cells; (b) Bxv1 mRNA expression is much 
higher when both Bxv1 and a retrovector are used to generate and 
select secondary infected cells (Figure 3B), suggesting that the 
dissemination of Bxv1 from cell to cell in a petri dish leaves many 
noninfected cells even after several weeks; (c) propagation was 
not observed under nonoptimized conditions, such as addition of 
half-diluted EndoC-βH1–conditioned medium to 293T cells with-
out polybrene (data not shown). Although some cells may be more 
permissive than 293T to Bxv1, our data indicate that inadvertent 
propagation can be easily avoided by good laboratory practices.
The most concerning problem appears to be the transcomple-
mentation of MuLV-based retrovectors by Bxv1. This means that 
transduction of EndoC-βH1/2 cells with such retrovectors led to 
their release in a xenotropic form, in addition to Bxv1, making 
possible an indefinite propagation of both viral particles in most 
mammalian proliferating cells, including those of human origin. 
This should be considered when potentially harmful transgenes 
are introduced into EndoC-βH1/2. In this case, other vectors 
should be preferred. Importantly, no SV40 T encoding lentiviral 
particles were detected in the conditioned medium of EndoC-βH1 
cells (data not shown). Thus, self-inactivating (SIN) lentivectors 
appear safer than MuLV-based retrovectors for stably transferring 
potentially harmful sequences in EndoC-βH1/2 cells.
Methods
See Supplemental Methods.
Statistics. Viral titer determination was expressed as TCID50 using 
the statistical Spearman-Kärber formula as previously described (13).
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